The study included 101 patients at 25 medical bone marrow transplant centers in the US, Europe, and Israel. The control group included 300 patients with characteristics similar to those of the participants in the study. The patients in the control group received two doses of double cord umbilical blood transplantation in 2006-10. The mortality rate among the patients who received StemEx was 15.8%, compared with a mortality rate of 24.5% among the patients in the control group.
On the basis of the results, Gamida Cell will apply to register StemEx, an allogeneic stem cell product, in the US and Europe.
In a separate development, Gamida Cell said that it was continuing the Phase I/II clinical trial of its NiCord product for the treatment of hereditary anemia and malignant blood diseases.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments